Here we characterized the biological sequelae of MALAT1 in MM, and we reported the first evidence of its druggability by a novel LNA gapmeR antisense oligonucleotide (ASO), which could lead to significant therapeutic advances in MM and other tumors. This evidence concerns the gene MALAT1 and Miyoshi myopathy.